Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

733 ARTÍCULOS , VIENDO DEL 241 AL 255

Calibrating microglia states in Alzheimer's disease: decoding immune-metabolic networks and nano-targeted multicomponent therapies

Xing JF, Mu K, Yan X, Yang X, Zhang D, Gao W, Zhang T, Yang S, Wang R, Zhang W, Zhu Y.

Front Immunol. 2026 Jun 16;17:1843978. doi: 10.3389/fimmu.2026.1843978. eCollection 2026.

Comparison of ABBV-552 Safety and Pharmacokinetics in Healthy Asian and Western Adults

Miles N, McNamee B, Zadikoff C, Boiser J, Shebley M, Boinpally R.

Clin Pharmacol Drug Dev. 2026 Jul;15(7):e70072. doi: 10.1002/cpdd.70072.

Exercise and fluoxetine in Alzheimer's disease: Molecular mechanisms of synergistic and antagonistic effects (Review)

Wu M, Li Y.

Int J Mol Med. 2026 Sep;58(3):237. doi: 10.3892/ijmm.2026.5908. Epub 2026 Jul 3.

White matter abnormalities in Alzheimer's disease: Implications for pathophysiology, diagnosis, and treatment

Chen Z, Yang K, Lin F, Tang W, Shi Y, Zhou S, Liu J, You Y.

Ageing Res Rev. 2026 Oct;121:103229. doi: 10.1016/j.arr.2026.103229. Epub 2026 Jul 5.

Targeting PARP1-dependent parthanatos in Alzheimer's disease: Mechanisms and therapeutic opportunities

Alameen AAM, Al-Kuraishy HM, Abdelaziz AM, Al-Gareeb AI, Albuhadily AK, Batiha GE.

Life Sci. 2026 Oct 1;402:124578. doi: 10.1016/j.lfs.2026.124578. Epub 2026 Jul 7.

Recent advances in Alzheimer's disease: From molecular mechanisms to therapeutic strategies

Rudman MD, Ulrich JD, Holtzman DM.

Cell. 2026 Jul 9;189(14):4193-4224. doi: 10.1016/j.cell.2026.06.006.

Attitudes of specialist memory-clinic patients with early symptomatic Alzheimer's disease towards lecanemab: results from a multicenter survey in Europe

Vöglein J, Levin J, Stögmann E, Haass C, Höglinger GU, Frölich L, Jessen F.

Sci Rep. 2026 Jul 9;16(1):21414. doi: 10.1038/s41598-026-61640-1.

Safety considerations of gene-based therapies for Alzheimer's disease

Bevins EA, Léger GC, Herman MA, Ringman JM, Roy S, Shtrahman M, Pa J, Feldman HH.

Alzheimers Dement. 2026 Jul;22(7):e71515. doi: 10.1002/alz.71515.

Targeting the APOE4-driven peripheral-central immune axis: A new frontier for Alzheimer's disease therapy

Shang Y, Zhai Z, Cong L, Dong X.

Pharmacol Res. 2026 Sep;231:108339. doi: 10.1016/j.phrs.2026.108339. Epub 2026 Jul 11.

Rethinking Anti-Inflammatory Therapy in Alzheimer's Disease: From Broad Suppression to Stage-State-Space Neuroimmune Reprogramming

Li X, Wang X, Dou J, Wang J, Xue F.

Cells. 2026 Jul 2;15(13):1208. doi: 10.3390/cells15131208.

Molecular Regulation of Pyroptosis in Alzheimer's Disease: Linking Neuroinflammation, Cell Death, and Therapeutic Targeting

Hsu CY, Raval AD, Bainsal N, Kaur I, Baig MR, Turakulov R, Sapaev I, Hjazi A, Alghazali T, Smerat A.

Mol Neurobiol. 2026 Jul 14;63(1):760. doi: 10.1007/s12035-026-06018-0.

Rethinking Alzheimer's Disease Therapy: From Amyloid-Centric Approaches to Multi-Target Phytochemical Strategies

Aktaş E, Yurt İ, Cerlet YN, Hanağası HA.

J Neurochem. 2026 Jul;170(7):e70506. doi: 10.1111/jnc.70506.

Microbes and Microbial Chemical Matter in the Seeding of Alzheimer's Disease: Prospects for Orthogonal Therapies

Kumar N, Yarlagadda V.

ACS Chem Neurosci. 2026 Aug 5;17(15):2858-2879. doi: 10.1021/acschemneuro.6c00255.

[Research progress on acupuncture-moxibustion regulating brain energy metabolism to intervene in Alzheimer's disease]

Li L, Hong C, Xie WT, Zhang RZ, Wei YT, Ma C, Yan XK.

Zhen Ci Yan Jiu. 2026 Jul 25;51(7):923-932. doi: 10.13702/j.1000-0607.20250813.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias